ストックスクリーナーアプリを入手
1.09
1.80%
-0.02
前日終値:
$1.11
開ける：
$1.13
24時間の取引高:
397.64K
Relative Volume:
0.75
時価総額：
$39.94M
収益：
-
当期純損益:
$-9.16M
株価収益率:
-1.9123
EPS:
-0.57
ネットキャッシュフロー:
$-8.75M
1週間 パフォーマンス:
-5.22%
1か月 パフォーマンス:
-17.42%
6か月 パフォーマンス:
+9.00%
1年 パフォーマンス:
+6.86%
1日の値動き範囲:
$1.05
$1.13
1週間の範囲:
$0.9834
$1.175
52週間の値動き範囲:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
名前
Renovorx Inc
セクター
電話
408-800-2649
住所
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.09 | 40.68M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Renovorx Inc (RNXT) 最新ニュース
Is RenovoRx Inc. stock dividend yield sustainable2025 Technical Overview & Low Drawdown Investment Strategies - newser.com
Intraday pattern recognizer results for RenovoRx Inc.2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
Is RenovoRx Inc. stock supported by innovation pipeline2025 Sector Review & Proven Capital Preservation Methods - newser.com
Tick level data insight on RenovoRx Inc. volatilityWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Can RenovoRx Inc. stock deliver consistent earnings growthTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Using AI based signals to follow RenovoRx Inc.2025 Sector Review & Safe Entry Point Alerts - newser.com
Is RenovoRx Inc. stock attractive for income investorsMarket Movers & Advanced Swing Trade Entry Plans - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Recap & Safe Capital Investment Plans - newser.com
Does RenovoRx Inc. fit your quant trading modelMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Will RenovoRx Inc. stock attract ESG investorsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
What analyst consensus says on RenovoRx Inc. stock2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Should I hold or sell RenovoRx Inc. stock in 20252025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
Why RenovoRx Inc. stock remains on watchlists2025 Dividend Review & Risk Managed Investment Strategies - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Evaluating RenovoRx Inc. with trendline analysisJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
First Patient Treated in RenovoCath Clinical Trial - Medical Product Outsourcing
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment - TipRanks
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update - TipRanks
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - The Manila Times
RenovoRx (Nasdaq: RNXT) to host Q3 2025 call; RenovoCath and Phase III TIGeR-PaC - Stock Titan
Renovorx Inc (RNXT) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.35%
大文字化:
|
ボリューム (24 時間):